Refractory IgA pemphigus successfully managed with adalimumab as monotherapy

J Dtsch Dermatol Ges. 2023 Dec;21(12):1560-1562. doi: 10.1111/ddg.15232. Epub 2023 Oct 24.

Authors

Juan José Lluch-Galcerá¹, Carmen Alcoverro¹, Eugeni Prat¹, Manel Martinez-Molina¹, Isabel Bielsa¹, Ariadna Quer², Julio Bassas¹

Affiliations

¹ Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Departament de Medicina, Universitat Autonoma de Barcelona (UAB), Badalona, Barcelona, Spain.
² Department of Pathology, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain.

PMID: 37875783
DOI: 10.1111/ddg.15232

No abstract available

Keywords: IgA Pemphigus; adalimumab; autoimmune blistering diseases; treatment.

Publication types

Letter

MeSH terms

Adalimumab / therapeutic use
Autoimmune Diseases*
Humans
Immunoglobulin A
Pemphigus* / drug therapy

Substances

Adalimumab
Immunoglobulin A